ArticleBMC microbiology2026
Antibacterial and anti-virulence activity of the repurposed agent SX-682 against Staphylococcus aureus.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) has become one of the most prevalent drug-resistant pathogens in many countries, posing a serious threat to global healthcare. Consequently, there is an urgent need to develop novel antibacterial agents.
objectivesThis study aimed to evaluate the antibacterial and antibiofilm activities of SX-682-an orally bioavailable allosteric inhibitor of CXCR1/2-against S. aureus and to elucidate its underlying mechanisms.
resultsOur findings demonstrate that SX-682 exhibits potent antibacterial activity against S. aureus, with minimum inhibitory concentration (MIC) values ranging from 8 to 16 µg/mL. Time-kill curves revealed a concentration-dependent bactericidal effect. Sub-inhibitory concentrations of SX-682 significantly inhibited the formation of S. aureus biofilms and effectively eradicated preformed mature biofilms. SX-682 enhances the membrane permeability of S. aureus and causes depolarization of the membrane potential, thereby damaging the integrity of the bacteria. By suppressing hemolytic activity and staphyloxanthin biosynthesis, SX-682 reduced the virulence of S. aureus. Additionally, proteomic analysis revealed that SX-682 treatment induced dysregulated expression of proteins in S. aureus, including SasG, FnbA, SdrC, SdrD, SaeR, SaeS, and SarX, which are associated with bacterial biofilm formation, bacterial virulence, and amino acid metabolism. Notably, in a murine model of MRSA-infected skin wounds, SX-682 significantly accelerated wound healing.
conclusionsCollectively, these findings highlight the considerable antibacterial and antibiofilm efficacy of SX-682 against S. aureus, supporting its potential as a promising therapeutic candidate for preventing and treating S. aureus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.